Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: DaiS who wrote (19769)	3/14/1999 7:33:00 PM
From: AlienTech	Respond to of 23519

Well I am still waiting for the study of hanging 10lbs bar bell's in the women's study.

To: DaiS who wrote (19769)	3/14/1999 7:38:00 PM
From: AlienTech	Respond to of 23519

>>1. The clitoris is small and uptake of alprostadil might be good, there may be not the problem with men of low efficiency of transfer between the corpus spongiosum and corpus cavernosum. However maybe viagra might give a better response throughout the genitalia. 2. It seems to be widely accepted in the US that a pill is the optimal approach. Many women might have a preference to use a cream over a pill. 3. The technique-bound muse method is easy for critics to ridicule compared with viagra. This disadvantage disappears with a cream.<< Take for example the stuff for yeast infection. How much would the medication cost? I would think a lot. And then take MCHM, as we saw, a cream aint the answer either. A pill aint the answer either. I wish MUSE was easier and american men would not be so squmesh about it. But they are really puddydats. They would prefer convenicence and danger rather than anything hard to do but much safer.

To: DaiS who wrote (19769)	3/14/1999 7:48:00 PM
From: Zebra 365	Read Replies (2) \| Respond to of 23519

BigKNY was transiently a VVUS investor (10 to 14 and out as I recall) but mostly sticks to Big Pharma, however he is also somewhat of a TA player and the TA on VVUS is looking better than it has in six months. I suspect he also hangs around this board because of the level of discussion. He is not an MD but has at least one sibling who is. "It would seem that Drs Kaplan and Berman would be as one in accepting that viagra causes increased blood flow to the female genitalia. But they are concerned with whether or this translates into increased sexual satisfaction?" DaiS, This is a big question. I used to joke that Dr. Goldstein thought that you make a dog happy by moving its tail back and forth. There are several forms of sexual dysfuction in women, anorgasmia, dysparunia, and decreased libido are probably the majors. Testosterone is a major driver of libido for men and women. Women who have persistent vasomotor symptoms on estrogen alone may be given a small amount of testosterone as in Estra-Test. I have used this also with some success in women who complain of decreased libido or anorgasmia on SSRI's (if they are already on an estrogen supplement.) Whether local changes in pelvic blood flow will affect a problem whose source is probably nearer the hippocampus, remains to be seen. Also I think alprostadil would be a poor choice for this use in women as there is a great risk of inducing spontaneous abortion using prostaglandins in women who are pregnant. However, alprostadil is generic and not patented by VVUS, many other safer vasodilators would be available for use under this patent. Zebra

To: DaiS who wrote (19769)	3/17/1999 11:25:00 PM
From: BigKNY3	Respond to of 23519

DaiS <<I could not see explicit reference to the Kaplan study not using placebos>> DaiS: I have a copy of the Kaplan study. Here are some quotes from the study that indicate the some of the difficulties in doing research in FSD: "There was no placebo arm in this study. The placebo effect of agents used to treat female sexual dysfunction is unknown." "Conclusions should be tempered by the small group of women and the short duration of follow-up. In addition, the entry criteria into this study was completely subjective....Moreover, the instrument used to assess efficacy, although modeled after a validated questionnaire in men, has not been validated. " The study concluded: "The results suggest that sildenafil is safe, although with limited efficacy in treating post-menopausal women with self-described sexual dysfunction. It should be emphasized that this study did not contain a placebo arm, was limited to postmenopausal women, and used only one dosage. Whether these results can be duplicated in larger and more varied populations remains to be determined. Nevertheless, the role of various agents in treating this heretofore underaddressed problem will be an exciting avenue of research in the future." BigKNY3